Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment

PURPOSE: Ciprofloxacin (CIP) has poor lung targeting after oral inhalation. This study developed optimized inhalable nanostructured lipid carriers (NLCs) for CIP to enhance deposition and accumulation in deeper parts of the lungs for treatment of noncystic fibrosis bronchiectasis (NCFB). METHODS: NL...

Descripción completa

Detalles Bibliográficos
Autores principales: Almurshedi, Alanood S, Aljunaidel, Hessah A, Alquadeib, Bushra, Aldosari, Basmah N, Alfagih, Iman M, Almarshidy, Salma S, Eltahir, Eram K D, Mohamoud, Amany Z
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012696/
https://www.ncbi.nlm.nih.gov/pubmed/33814907
http://dx.doi.org/10.2147/IJN.S286896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012696/
https://www.ncbi.nlm.nih.gov/pubmed/33814907
http://dx.doi.org/10.2147/IJN.S286896

Ejemplares similares